1 minute reading time (40 words)

Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications

Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, signs an exclusive license for two patent pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University. Read more. 

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More